TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8279247
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion for 25 min and thereafter isoflurane (Group B)
Study: 8279247
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion throughout the procedure (Group C)
Study: 2876923
Drug: Tulobuterol 30
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol 30 mcg/kg twice daily
Study: 2876923
Drug: Terbutaline 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 75 mcg/kg three times daily
Study: 2876923
Drug: Tulobuterol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol (various doses 10 to 60 mcg/kg)
Study: 2876923
Drug: Tulobuterol 30
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol 30 and 40 mcg/kg twice daily
Study: 22633722
Drug: Intravenous contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous contrast alone (IV)
Study: 22633722
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral contrast (IVO)
Study: 18546896
Drug: Propofol (PRO)
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol (PRO) 1‐3 mg x kg(‐1) x hr(‐1)
Study: 15802769
Drug: Bisphosphonates (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates (long-term treatment)
Study: 10621536
Drug: Human amniotic
Normalized name: Human Amniotic Fluid
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human amniotic membrane adjunct use
Study: 8803365
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss treatment (21.1 +/- 8.4 kg lost after 6 months)
Study: 6123837
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir therapy (500 mg/m2 intravenously 3 times daily for 5 days)
Study: 30977398
Drug: 10 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weekly group sessions of manualized memory rehabilitation plus usual care
Study: 28535810
Drug: bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate 400 mg qid for 21 days
Study: 25495359
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy (ET)
Study: 17901953
Drug: PF (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF (cisplatin 100 mg/m² i.v. Day 1 and 5-FU 1,000 mg/m² per day i.v. continuous infusion D1-D5, every 21 days)
Study: 17901953
Drug: UFTVP (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFTVP (cisplatin 100 mg/m² i.v. Day 1; UFT 200 mg/m² per day p.o. D1-D21 and vinorelbine 25 mg/m² i.v. D1 and D8, every 21 days)
Study: 10463173
Drug: Vaccinated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated with two acellular and one whole-cell pertussis vaccine
Study: 10463173
Drug: B. pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: B. pertussis strains used in vaccines
Study: 7841012
Drug: Caries Meter
Normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caries Meter L
Study: 29440016
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of POC CRP and BISNA
Study: 20217230
Drug: Forensic assertive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forensic assertive community treatment (FACT)
Study: 12086199
Drug: Flunisolide HFA
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide HFA (340 microg daily)
Study: 12086199
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (6400 microg daily)
Study: 12086199
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) (336 microg daily)
Study: 10429772
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of droperidol and dolasetron (10 micrograms x kg‐1 + 12.5 mg)
Study: 7593515
Drug: Microlaparoscope <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microlaparoscope < 2.0 mm diameter under analgesic sedation plus local anaesthesia (group II)
Study: 2105990
Drug: Budesonide aerosol
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aerosol (4 weeks treatment)
Study: 25719620
Drug: Paravertebral blocks
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral blocks (PVB) and total intravenous anesthesia
Study: 25719620
Drug: Sham subcutaneous
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham subcutaneous injections and standardized general anesthesia
Study: 8591720
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg 14C-labeled meloxicam (intravenous infusion)
Study: 8591720
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg 14C-labeled meloxicam (oral solution)
Study: 2649022
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (20 ml containing 9% gamma-linolenic acid)
Study: 14577658
Drug: CLA supplementation
Normalized name: CLA
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLA supplementation (2.1 g daily for 45 days)
Study: 8923023
Drug: Supplements of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplements of vitamins (with or without other antioxidants)
Study: 1738797
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of theophylline (400 mg)
Study: 1738797
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of theophylline (300 mg b.d. for 4 weeks)
Study: 6395773
Drug: Prednisolone 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 0.75 mg/kg/day
Study: 6395773
Drug: Prednisolone 1.25
Normalized name: prednisolone 1.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1.25 mg/kg/day
Study: 30736773
Drug: Additional periarticular
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional periarticular injection (40 mg methylprednisolone, 150 mg ropivacaine, 0.1 mg epinephrine)
Study: 30736773
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional injection
Study: 29248359
Drug: Elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elosulfase alfa enzyme replacement therapy (ERT), administered weekly for 96 weeks.
Study: 29248359
Drug: Elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elosulfase alfa ERT (continuously treated patients), administered weekly for 96 weeks.
Study: 17205319
Drug: Risperidone 1
Normalized name: risperidone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 1 mg
Study: 18444492
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) - 3x2 injections into both nasal cavities for 4 weeks
Study: 18444492
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - intranasal physiologic saline
Study: 17294999
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of 0.9% sodium chloride (control group)
Study: 7930473
Drug: Interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha‐2b with prednisolone in decreasing doses of 60, 40, 20 mg for 6 weeks
Study: 3332914
Drug: ciladopa 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciladopa 15 mg b.i.d.
Study: 3332914
Drug: ciladopa 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciladopa 5 mg b.i.d.
Study: 29860362
Drug: Social modeling
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social modeling of side effects (placebo treatment)
Study: 24713545
Drug: AEZS-108 (267mg/m²,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEZS-108 (267mg/m², equimolar to 76.8mg/m² of free doxorubicin) every 3 weeks as a two-hour i.v. infusion
Study: 20151839
Drug: Maraviroc (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (300 mg once or twice daily) with zidovudine-lamivudine
Study: 20151839
Drug: Efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (600 mg once daily) with zidovudine-lamivudine
Study: 20151839
Drug: Maraviroc (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (300 mg once or twice daily)
Study: 15896918
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dexamethasone suppression test (DST) in BPD patients with comorbid PTSD
Study: 15896918
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dexamethasone suppression test (DST) in total BPD group
Study: 15896918
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dexamethasone suppression test (DST) in healthy controls
Study: 15896918
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dexamethasone suppression test (DST) in BPD patients without PTSD
Study: 10066854
Drug: Additional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional treatment by a qualified physiotherapist
Study: 10066854
Drug: Additional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional treatment by a physiotherapy assistant
Study: 8828605
Drug: Dietary restriction
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary restriction of phenylalanine (continued therapy)
Study: 8828605
Drug: Dietary restriction
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary restriction of phenylalanine (discontinued therapy)
Study: 1564674
Drug: Future oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Future oriented hypnotic imagery presented as hypnosis
Study: 1564674
Drug: Future oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Future oriented hypnotic imagery not presented as hypnosis
Study: 3932499
Drug: 2% cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% cromolyn sodium (CS) ophthalmic solution, used six times daily for 5 weeks
Study: 3932499
Drug: Placebo, used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, used six times daily for 5 weeks
Study: 26414976
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for pain
Study: 19813008
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg oral salmon calcitonin (sCT) at 08:00
Study: 19813008
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg oral salmon calcitonin (sCT) at 17:00
Study: 19813008
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg oral salmon calcitonin (sCT) at 22:00
Study: 19813008
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg oral salmon calcitonin (sCT) twice daily for 14 days at 08:00
Study: 19813008
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg oral salmon calcitonin (sCT) twice daily for 14 days at 17:00
Study: 7749977
Drug: Ebastine 1
Normalized name: ebastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 1 mg
Study: 7749977
Drug: Ebastine 3
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 3 mg
Study: 1546142
Drug: moclobemide, 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide, 450 mg/j
Study: 1546142
Drug: viloxazine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: viloxazine, 300 mg/j
Study: 1546142
Drug: maprotiline, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: maprotiline, 150 mg/j
Study: 6375537
Drug: Propranolol (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (480 mg/day for 6 weeks)
Study: 6375537
Drug: Verapamil (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (480 mg/day for 6 weeks)
Study: 22332827
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (NE) at 59 μmol/L
Study: 22332827
Drug: Vasopressin (VP)
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin (VP) at 100 nmol/L
Study: 20688574
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (2 mg folic acid, 25 mg vitamin B6, and 0.5 mg vitamin B12)
Study: 18044297
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (bupivacaine 0.25% 6-10 ml + fentanyl 50-100 microg, followed by bupivacaine 0.125% + fentanyl 1-2 microg/ml at 6-12 ml/h)
Study: 11816327
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA), initial dose of 10-15 mg/kg given 10-15 minutes before tourniquet release, with possible repeat doses every 6-8 hours during the first postoperative day.
Study: 31162140
Drug: NT-proBNP predictive
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP predictive ability among black individuals with obesity (BMI ≥ 30 kg/m2) or eGFR < 60 mL/min/1.73 m2
Study: 28738079
Drug: Ozone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone (20 μg/ml)
Study: 23835693
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (DCCT)
Study: 23835693
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (DCCT)
Study: 11339520
Drug: Oral suspension
Normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension of meloxicam 7.5 mg daily
Study: 11339520
Drug: Solid formulation
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid formulation of meloxicam 15 mg
Study: 9213408
Drug: Icelandic Moss
Normalized name: Oak moss
DrugBank: Evernia prunastri (DB14172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icelandic Moss (Cetraria islandica) lozenges, 0.48 g per day (10 lozenges per day)
Study: 7864949
Drug: Albuterol delivered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol delivered by metered-dose inhaler (MDI)
Study: 3666666
Drug: pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirenzepine 50 mg b.i.d.
Study: 30224261
Drug: CHA2DS2‐VASc based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHA2DS2‐VASc based anticoagulant treatment recommendation
Study: 20553856
Drug: Repeated antenatal
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated antenatal corticosteroid treatment
Study: 20553856
Drug: Single antenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antenatal corticosteroid treatment
Study: 12929196
Drug: Intramuscular caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular caffeine injection (0.5 ml, 20 mM)
Study: 10812530
Drug: Pramipexole 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 1.0 mg per day
Study: 10812530
Drug: Pramipexole 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 5.0 mg per day
Study: 8692301
Drug: Endoscopic CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic CO2 laser vaporization treatment
Study: 1519524
Drug: Angina-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angina-directed medical therapy
Study: 1519524
Drug: Angina plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angina plus ambulatory electrocardiographic-directed medical therapy
Study: 6234281
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg bd norfloxacin
Study: 6234281
Drug: 160/800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160/800 mg bd cotrimoxazole
Study: 29633025
Drug: 200-μg vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-μg vaginal misoprostol, 3 hours prior to vaginoscopic hysteroscopy
Study: 26541687
Drug: Antidepressants (sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (sertraline and mianserin)
Study: 26541687
Drug: Flexible cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible cognitive-behavioural therapy (CBT)
Study: 26541687
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of psychotherapy and medicine
Study: 19286598
Drug: Treatment arms
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arms from various clinical trials for acute stroke
Study: 19286598
Drug: National Institute
Normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: National Institute of Neurological Diseases and Stroke intravenous recombinant tissue plasminogen activator trial
Study: 19286598
Drug: Stroke‐Acute Ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke‐Acute Ischemic NXY Treatment and Abciximab Emergent Stroke Treatment Trial
Study: 11879254
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg (intravenous)
Study: 11879254
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg (oral) in fed state
Study: 11879254
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg (oral) in fasted state
Study: 11879254
Drug: Sildenafil doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil doses of 25, 50, 100, and 200 mg (oral)
Study: 11879254
Drug: Sildenafil (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (various doses)
Study: 7721431
Drug: Intralipid/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid/heparin
Study: 7721431
Drug: saline/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline/heparin
Study: 7721431
Drug: dextrose/heparin
Normalized name: DEXTROSE/HEPARIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextrose/heparin
Study: 1645503
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral therapy with azithromycin
Study: 1645503
Drug: Standard 7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 7-day twice-daily course of doxycycline
Study: 31034640
Drug: 300 min/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 min/wk aerobic exercise (HIGH dose group)
Study: 31034640
Drug: 150 min/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 min/wk aerobic exercise (MODERATE dose group)
Study: 26930244
Drug: Medulla powder
Normalized name: Cyathea medullaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medulla powder (15 g/day)
Study: 26930244
Drug: Whole fruit
Normalized name: Astragalus exscapus whole flowering-fruiting extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole fruit powder (15 g/day)
Study: 17634728
Drug: Dentifrice containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice containing 550 microg F/g, pH 5.5 (experimental)
Study: 17634728
Drug: Dentifrice containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice containing 1, 100 microg F/g, pH 7.0 (positive control)
Study: 15070956
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (1.3 g, 57 mmol)
Study: 15070956
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium diet (4 g, 172 mmol)
Study: 8064943
Drug: Chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine phosphate (5 mg base kg‐1)
Study: 8064943
Drug: Placebo (multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multivitamin tablet)
Study: 1200338
Drug: Intramuscular chlorprothixene
Normalized name: chlorprothixene
DrugBank: Chlorprothixene (DB01239)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular chlorprothixene (1 mg/kg)
Study: 1200338
Drug: Oral chlorprothixene
Normalized name: chlorprothixene
DrugBank: Chlorprothixene (DB01239)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chlorprothixene (4% solution, 1.5-2 mg/kg)
Study: 1200338
Drug: Intramuscular 1-hyoscyamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 1-hyoscyamine (0.005-0.01 mg/kg)
Study: 26001837
Drug: Cardiac output-guided
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac output-guided haemodynamic therapy
Study: 10661690
Drug: Alcohol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (75 ml)
Study: 9403805
Drug: TRH injection
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TRH injection (0.2 mg protirelin, iv)
Study: 9403805
Drug: Atropine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1 mg, iv)